MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
11.25
+1.00
+9.72%
Opening 13:03 07/08 EDT
OPEN
10.33
PREV CLOSE
10.25
HIGH
11.47
LOW
10.32
VOLUME
3.99M
TURNOVER
--
52 WEEK HIGH
28.18
52 WEEK LOW
5.90
MARKET CAP
1.16B
P/E (TTM)
-2.1507
1D
5D
1M
3M
1Y
5Y
1D
INTELLIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 22h ago
Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital
TipRanks · 1d ago
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
NASDAQ · 1d ago
Weekly Report: what happened at NTLA last week (0630-0704)?
Weekly Report · 1d ago
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Benzinga · 1d ago
Insider Sales Shake Royal Caribbean, Kroger, HP, Intellia, EOG
TipRanks · 3d ago
Intellia Therapeutics Executive Makes Significant Stock Sale
TipRanks · 4d ago
Weekly Report: what happened at NTLA last week (0623-0627)?
Weekly Report · 06/30 12:10
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.